Retatrutide is an innovative triple agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. It is being developed for the treatment of type 2 diabetes and obesity. By simultaneously activating these receptors, Retatrutide enhances insulin secretion, reduces appetite, and improves metabolic control. Early clinical trials have demonstrated its potential for significant weight loss and glycemic improvement.
link:http://www.tirz-peptide.com